Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: Therapeutic opportunities and controversies

Microcirculation

Volumn 10, Issue 3-4, 2003, Pages 247-257

  Daly, Christine ^a,b   Rollins, Barrett J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chemokine; Inflammation; T helper cell

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN E; BETA INTERFERON; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR2; DNA; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN; PEPTIDE DERIVATIVE; RECEPTOR ANTIBODY; RECEPTOR BLOCKING AGENT;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; ARTICLE; ATHEROSCLEROSIS; CELL INFILTRATION; CELL MATURATION; CELL POLARITY; CELLULAR IMMUNITY; DNA MODIFICATION; DRUG MECHANISM; GENE DELIVERY SYSTEM; GENE THERAPY; HELPER CELL; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNIZATION; INFLAMMATORY DISEASE; LEISHMANIASIS; LUNG GRANULOMA; LYMPHOCYTE FUNCTION; MEMORY CELL; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MONOCYTE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RESTENOSIS; SCREENING TEST; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT INDICATION; ADAPTATION; ANIMAL; IMMUNITY; IMMUNOLOGY; INFLAMMATION; METABOLISM; REVIEW;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CHEMOKINE CCL2; HUMANS; IMMUNITY; INFLAMMATION;

EID: 0242273334     PISSN: 10739688     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mn.7800190     Document Type: Article

References (73)

1. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Natoli E, Rollins BJ, Milos PM. (1999). Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 19:1518-1525.
2. Alam R, Lett-Brown MA, Forsythe PA, Anderson-Walters DJ, Kenamore C, Kormos C, Grant JA. (1992). Monocyte chemotactic and activating factor is a potent histamine-releasing factor for basophils. J Clin. Invest 89:723-728.
3. Banisadr G, Queraud-Lesaux F, Boutterin MC, Pelaprat D, Zalc B, Rostene W, Haour F, Parsadaniantz SM. (2002). Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain. J Neurochem 81:257-269.
4. Bischoff SC, Krieger M, Brunner T. Dahinden CA. (1992). Monocyte chemotactic protein 1 is a potent activator of human basophils. J Exp Med 125:1271-1275.
5. Boisvert WA, Curtiss LK, Terkeltaub RA. (2000). Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res 21:129-137.
6. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE, Charo IF. (1997). Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 100:2552-2561.
7. - mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894-897.
8. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. (1994). Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 91:3652-3656.
9. Chensue SW, Warmington KS, Lukacs NW, Lincoln PM, Burdick MD, Strieter RM, Kunkel SL. (1995). Monocyte chemotactic protein expression during schistosome egg granuloma formation. Sequence of production, localization, contribution, and regulation. Am J Pathol 146:130-138.
10. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, Paloscia L, Materazzo G, D'Annunzio E, Conti P, Chiarelli F, Cuccurullo F, Mezzetti A. (2001). Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21:327-334.
11. Clinton SK, Libby P. (1992). Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 116: 1922-1300.
12. Coughlan CM, McManus CM, Sharron M, Gao Z, Murphy D, Jaffer S, Choe W, Chen W, Hesselgesser J, Gaylord H, Kalyuzhny A, Lee VM, Wolf B, Dores RW, Kolson DL. (2000). Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons. Neuroscience 97:591-600.
13. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. (1990). Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 87:5134-5138.
14. Egashira K, Koyanagi M, Kitamoto S, Ni W, Kataoka C, Morishita R, Kaneda Y, Akiyama C, Nishida KI, Sueishi K, Takeshita A. (2000). Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis. FASEB J 14:1974-1978.
15. Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo IF, Nishida K, Inoue S, Katoh M, Ichiki T, Takeshita A. (2002). Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 90:1167-1172.
16. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. (2000). CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 192:899-905.
17. Fuentes ME, Durham SK, Swerdel MR, Lewin AC, Barton DS, Megill JR, Bravo R, Lira SA. (1995). Controlled recruitment of monocytes/macrophages to specific organs through transgenic expression of MCP-1. J Immunol 155:5769-5776.
18. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, Luster AD, Luscinskas FW, Rosenzweig A. (1999). MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398:718-723.
19. 2-terminal residues. J Exp Med 181:631-640.
20. Gonzalo JA, Lloyd CM, Wen D, Albar JP, Wells TN, Proudfoot A, Martinez AC, Dorf M, Bjerke T, Coyle AJ, Gutierrez-Ramos JC. (1998). The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 188:157-167.
21. Cosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. (1999). MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103:773-778.
22. Grewal IS, Rutledge BJ, Fiorillo JA, Gu L, Gladue RP, Flavell RA, Rollins BJ. (1997). Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes: abrogation by a second transgene expressing systemic MCP-1. J Immunol 159:401-408.
23. Groot PHE, Valdes AM, Kaur R, Berkhout TA, Wolfe ML, O'Brien EJ, Spurr NK, Gefter W, Rut A, Bond B, Bridges A, Rader DJ. (2001) A Val64Ile mutation in CCR2B is associated with reduced atherosclerosis and decreased signaling. Paper presented at: Keystone Conference on Chemokines and Chemokine Receptors, Taos, NM. Feb. 16-21, 2001.
24. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. (1998). Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2:275-281.
25. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. (2000). Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404:407-411.
26. Gunn MD, Nelken NA, Liao X, Willimas LT. (1997). Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activation. J Immunol 158:376-383.
27. Handel TM, Domaille PJ. (1996). Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry 35:6569-6584.
28. Horvath C, Welt FG, Nedelman M, Rao P, Rogers C. (2002). Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res 90:488-494.
29. Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM. (2001). Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 193:713-726.
30. Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M, Jung S, Littman DR, Ley K. (2001). The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest 108:1307-1314.
31. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. (2000). Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 192:1075-1080.
32. Jiang Y, Beller DI, Frendl G, Graves DT. (1992). Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 148:2423-2428.
33. Karpus WJ, Kennedy KJ. (1997). MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 62:681-687.
34. Karpus WJ, Lukacs NW, Kennedy KJ, Smith WS, Hurst SD, Barrett TA. (1997). Differential CC chemokine-induced enhancement of T helper cell cytokine production. J Immunol 158:4129-4136.
35. Kim SY, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF. (1995). Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. Kidney Int 48:363-371.
36. Kim Y, Sung S, Kuziel WA, Feldman S, Fu SM, Rose CE Jr. (2001). Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2). J Immunol 166:5183-5192.
37. Koh KK, Son JW, Ahn JY, Choi YM, Jin DK, Park GS, Choi IS, Sohn MS, Shin EK. (2001). Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet. Coron Artery Dis 12:305-311.
38. Kuna P, Reddigari SR, Rucinski D, Oppenheim JJ, Kaplan AP. (1992). Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils. J Exp Med 175:489-493.
39. Lu B, Rutledge BJ, Cu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ. (1998). Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 187:601-608.
40. Lubkowski J, Bujacz C, Boque L, Domaille PJ, Handel TM, Wlodawer A. (1997). The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions. Nat Struct Biol 4:64-69.
41. MacLean JA, De Sanctis GT, Ackerman KG, Drazen JM, Sauty A. DeHaan E, Green FH, Charo IF, Luster AD. (2000). CC chemokine receptor-2 is not essential for the development of antigen-induced pulmonary cosinophilia and airway hyperresponsiveness. J Immunol 165:6568-6575.
42. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. (1989). Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 169:1485-1400.
43. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF. (1998). MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 86:20-29.
44. Middleton J, Neil S, Wintle J, Clark-Lewis I, Moore H, Lam C, Auer M, Hub E, Rot A. (1997). Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91:385-395.
45. Mori E, Komori K, Yamaoka T, Tanii M, Kataoka C, Takeshita A, Usui M, Egashira K, Sugimachi K. (2002). Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation 105:2905-2910.
46. Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M. (1990). Neutrophil-activating properties of the melanoma growth-stimulating activity, MGSA. J Exp Med 171:1797-1802.
47. Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T, Inoue N, Hirata K, Matsukawa A, Morishita R, Kaneda Y, Yokoyama M. (2002). Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. Arterioscler Thromb Vasc Biol 22:115-120.
48. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. (1991). Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88:1121-1127.
49. Ni W, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, Inoue S, Imaizumi K, Akiyama C, Nishida Ki K, Takeshita A. (2001). New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 103:2096-2101.
50. Oshima S, Ogawa H, Hokimoto S, Nakamura S, Noda K, Saito T, Socjima H, Takazoe K, Ishibashi F, Yasue H. (2001). Plasma monocyte chemoattractant protein-1 antigen levels and the risk of restenosis after coronary stent implantation. Jpn Circ J 65:261-264.
51. Paavola CD, Hemmerich S, Grunberger D, Polsky I, Bloom A, Freedman R, Mulkins M, Bhakta S, McCarley D, Wiesent L, Wong B, Jarnagin K, Handel TM. (1998). Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. J Biol Chem 273:33157-33165.
52. Paolini JF, Willard D, Consler T, Luther M, Krangel MS. (1994). The chemokines IL-8, monocyte chemoattractant protein-1 and I-309 are monomers at physiologically relevant concentrations. J Immunol 153:2704-2717.
53. Peters W, Dupuis M, Charo IF. (2000). A mechanism for the impaired IFN-gamma production in C-C chemokine receptor 2 (CCR2) knockout mice: role of CCR2 in linking the innate and adaptive immune responses. J Immunol 165:7072-7077.
54. Peters W, Scott HM, Chambers HF, Flynn JL, Charo IF, Ernst JD. (2001). Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci USA 98:7958-7963.
55. Poon M, Megyesi J, Green RS, Zhang H, Rollins BJ, Safirstein R, Taubman MB. (1991). In vivo and in vitro inhibition of JE gene expression by glucocorticoids. J Biol Chem 266:22375-22379.
56. Ransohoff RM, Hamilton TA, Tani M, Stoler MH, Shick HE, Major JA, Estes ML, Thomas DM, Tuohy VK. (1993). Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis, FASEB J 7:592-600.
57. Rodriguez-Frade JM, Vila-Coro AJ, de Ana AM, Albar JP, Martinez AC, Mellado M. (1999). The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. Proc Natl Acad Sci USA 96:3628-3633.
58. Rollins BJ, Walz A, Baggiolini M. (1991). Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 78:1112-1116.
59. Ross R. (1986). The pathogenesis of atherosclerosisan update. N Engl J Med 314:488-500.
60. Rutledge BJ, Rayburn H, Rosenberg R, North RJ, Gladue RP, Corless CL, Rollins BJ. (1995). High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J Immunol 155:4838-4843.
61. Sato N, Ahuja SK, Quinones M, Kostecki V, Reddick RL, Melby PC, Kuziel WA, Ahuja SS. (2000). CC chemokine receptor (CCR)2 is required for langerhans cell migration and localization of T helper cell type 1 (Th1)-inducing dendritic cells: absence of CCR2 shifts the Leishmania major-resistant phenotype to a susceptible state dominated by Th2 cytokines, B cell outgrowth, and sustained neutrophilic inflammation. J Exp Med 192:205-218.
62. Schecter AD, Rollins BJ, Zhang YJ, Charo IF, Fallon JT, Rossikhina M, Giesen PL, Nemerson Y, Taubman MB. (1997). Tissue factor is induced by monocyte chemoattratant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 272:28568-28573.
63. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. (1998). Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 84:238-249.
64. Stricter RM, Wiggins R, Phan SH, Wharram BL, Showell HJ, Remick DG, Chensue SW, Kunkel SL. (1989). Monocyte chemotactic protein gene expression by cytokine-treated human fibroblasts and endothelial cells. Biochem Biophys Res Commun 162: 694-700.
65. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B, Horvath L, Csaszar A. (2001). Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD): coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 158:233-239.
66. Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, Nadal-Ginard B. (1992). JE mRNA accumulates rapidly in aortic injury and in PDGF-stimulaled vascular smooth muscle cells. Circ Res 70: 314-325.
67. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. (1998). Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285.
68. Van Der Voorn P, Tekstra J, Beelen RH, Tensen CP, Van Der Valk P, De Groot CJ. (1999). Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 154:45-51.
69. Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter RM. (1991). Structure and neutrophilactivating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 174:1355-1362.
70. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. (1991). Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88:5252-5256.
71. Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu JI, Leonard EJ. (1989). Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med 169:1449-1459.
72. Zhang Y, Rollins BJ. (1995). A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol Cell Biol 15: 4851-4855.
73. Zhang YJ, Rutledge BJ, Rollins BJ. (1994). Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis: identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J Biol Chem 269:15918-15924.